Literature DB >> 26018438

The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis.

Marta Calatroni1, Carlo Buzio2, Augusto Vaglio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26018438     DOI： 10.1093/rheumatology/kev196

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

Review 1.  Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment.

Authors:  Farid Arman; Marina Barsoum; Umut Selamet; Hania Shakeri; Olivia Wassef; Mira Mikhail; Anjay Rastogi; Ramy M Hanna
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-22

Review 2.  Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases.

Authors:  Shing Yi Pan; Yvonne Cashinn Chia; Hui Rong Yee; Angelina Ying Fang Cheng; Clarice Evey Anjum; Yenny Kenisi; Mike Ks Chan; Michelle Bf Wong
Journal:  Future Sci OA       Date:  2020-10-29

3.  Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy.

Authors:  Raja Ramachandran; Vinod Kumar; Joyita Bharati; Brad Rovin; Ritambhra Nada; Vivek Kumar; Manish Rathi; Vivekanand Jha; Krishan Lal Gupta; Harbir Singh Kohli
Journal:  Kidney Int Rep       Date:  2021-08-10

4.  Risk of Cancer in Connective Tissue Diseases in Northeastern Italy over 15 Years.

Authors:  Elena Treppo; Federica Toffolutti; Valeria Manfrè; Martina Taborelli; Ginevra De Marchi; Salvatore De Vita; Diego Serraino; Luca Quartuccio
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.